Phaim Pharma is dedicated to developing potentially curative treatments for auto-immune diseases. The UK based company is developing a range of novel therapeutic innovations including an exciting new therapy to treat and prevent type 1 diabetes as well as a predictive biomarker kit for first-degree relatives of people with type 1 diabetes. Our long-term goal is the broadening of our platform approach to other autoimmune diseases, such as psoriasis, through our active R & D programme. Our team is dedicated on improving lives of people with diabetes and other autoimmune diseases. We work with world-class companies to deliver life-changing therapies as 'good enough' is no longer good enough.